Please assess the completion status of the following clinical trial:

Trial Title: Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Experience dose-limiting symptoms at or before the challenge dose of peanut protein on screening and not experiencing dose-limiting symptoms to placebo as defined in the protocol~* Serum Immunoglobulin E (IgE) to peanut of ≥10 kUA/L and/or a skin prick test (SPT) to peanut ≥8 mm compared to a negative control~* Participants/legal guardians must be trained on the proper use of the epinephrine autoinjector device to be allowed to enroll in the study~* Participants with other known food allergies must agree to eliminate these other food items from their diet so as not to confound the safety and efficacy data from the study~Key Exclusion Criteria:~* History of other chronic disease (other than asthma, Atopic Dermatitis (AD), or allergic rhinitis) requiring therapy (eg, heart disease, diabetes, hypertension) that would represent a risk to participant's health or safety in this study or ability to comply with study protocol~* History of frequent or recent severe, life-threatening episode of anaphylaxis or anaphylactic shock~* History of eosinophilic Gastrointestinal (GI) disease~* Asthma at time of enrollment with any of the following:~  * Forced Expiratory Volume 1 Second (FEV1) \<80% of predicted or ratio of FEV1 to forced vital capacity (FEV1/FVC) \<75% of predicted with or without controller medications~ * Inhaled corticosteroids (ICS) dosing of daily fluticasone (or equivalent ICS based on NHLBI dosing chart)~ * One hospitalization in the past year for asthma~ * Emergency room visit for asthma within 6 months prior to screening~* Use of systemic corticosteroids within 2 months prior to screening~* Use of other forms of allergen immunotherapy or immunomodulatory therapy within 3 months prior to screening~* Use of any agents known or likely to interact with epinephrine (eg, beta-blockers, angiotensin converting enzyme-inhibitors, tri-cyclic antidepressants, or other drugs), within 3 weeks prior to screening~* Allergy to oat (placebo in DBPCFC)~Note: Other protocol Inclusion/Exclusion Criteria apply

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- dupilumab + AR101 (Type: EXPERIMENTAL): Participant randomization of a ratio of 2 active dupilumab arms
- placebo matching dupilumab + AR101 (Type: EXPERIMENTAL): Participant randomization of a ratio of 1 placebo arm

Based on this trial design, predict the completion outcome and termination type (if applicable).